Abstract
The inverse relationship between plasma high density lipoproteins (HDL) and cardiovascular risk, though amply documented in the 1960s (Gofman et al. 1966), was not widely appreciated until its re-emphasis in the publication of Miller and Miller (1975). Even now, despite the weight of evidence supporting the concept, our understanding of the mechanism which underlies it remains rudimentary. The most popular view (Miller 1984) endows the lipoprotein with the capacity to accept cholesterol from parenchymal cells, possibly following its interaction with a membrane receptor which recognises the major apolipoprotein A component of the particle. Esterification of the assimilated sterol by lecithin:cholesterol acyltransferase leads to its entrapment within the hydrophobic core of the particle which expands and limits continued cholesterol uptake. At this point it is envisaged that further cycles of sterol capture depend upon transfer of the core ester into less dense lipoproteins. These apolipoprotein B-containing very low and low density lipoproteins (VLDL and LDL) are probably responsible for the ultimate delivery of sterol to the liver, so making centripetal cholesterol transport dependent on the integrated activities of all major plasma lipoprotein fractions. Thus, it is not surprising that most prescribed hypo-lipidaemic drugs, which were originally designed to lower plasma VLDL and LDL, should also have an impact on HDL metabolism.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Atmeh RF, Shepherd J, Packard CJ (1983) Subpopulations of apolipoprotein AI in human high density lipoporteins. Biochim Biophys Acta 751:175–188
Beamot HR, Glickman RM, Weinberg L, Green PHR, Tall A (1982) Effects of biliary diversion on rat mesenteric lymph apolipoprotein AI and high density lipoprotein. J Clin Invest 69:210–217
Eisenberg S, Gavish D, Kleinman Y (1986) Bezafibrate. In: Fears R, Levy RI, Shepherd J, Packard CJ, Miller NE (eds) Pharmacological control of hyperlipidaemia. Prous, Barcelona, pp 145–170
Gofman JW, Young W, Tandy R (1986) Ischaemic heart disease, atherosclerosis and longevity. Circulation 34:679–697
Miller NE (1984) Current concepts of the role of HDL in reverse cholesterol transport. In: Miller NE, Miller GJ (eds) Clinical and metabolic aspects of high density lipoproteins. Elsevier, Amsterdam, pp 187–216
Miller NE, Miller GJ (1975) Plasma high density lipoprotein concentration and the development of ischaemic heart disease. Lancet i:16–19
Packard CJ, Shepherd J (1982) The hepatobiliary axis and lipoprotein metabolism. J Lipid Res 23:1081–1098
Shepherd J, Packard CJ (1984) High density lipoprotein apoprotein metabolism. In: Miller NE, Miller GJ (eds) Clinical and metabolic aspects of high density lipoproteins. Elsevier, Amsterdam, pp 247–274
Sherpherd J, Packard CJ, Stewart JM, Atmeh RF, Clark DS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG, Lawrie TDV (1984) Apolipoprotein A and B (Sf 100–400) metabolism during Bezafibrate therapy in hypertriglyceridernie subjects. J Clin Invest 74:2164–2177
The Lipid Research Clinics Coronary Primary Prevention Trial Results (1984) 1 Reduction in incidence of coronary heart disease. Lipid Res Clin Progr. JAMA 251:351–364
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Shepherd, J., Packard, C.J. (1987). Effects of Lipid-Lowering Drugs on High Density Lipoprotein Structure and Metabolism. In: Paoletti, R., Kritchevsky, D., Holmes, W.L. (eds) Drugs Affecting Lipid Metabolism. Proceedings in Life Sciences. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71702-4_37
Download citation
DOI: https://doi.org/10.1007/978-3-642-71702-4_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-71704-8
Online ISBN: 978-3-642-71702-4
eBook Packages: Springer Book Archive